OKYO Pharma Limited (OKYO) Max Pain Analysis
Max pain is the strike price where aggregate option buyer payout is minimized at expiration. It represents the price at which option writers retain the most premium.
OKYO Pharma Limited (OKYO) operates in the Healthcare sector, specifically the Biotechnology industry, with a market capitalization near $64.8M, listed on NASDAQ, employing roughly 3 people, carrying a beta of -0.05 to the broader market. OKYO Pharma Limited, a preclinical biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Led by Robert J. Dempsey, public since 2022-05-17.
Max pain analysis shows the strike price where the most options expire worthless. No recent options activity for OKYO as of 2026-06-01; this typically reflects low options liquidity, a recently listed name, or a temporary data feed delay. Snapshot will refresh on the next active session.